The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry-Reference-Cited by-同舟云学术

The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry

Published:2023-11-14 Issue:12 Volume:25 Page:2333-2336
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Martyn Trejeeve¹,Saef Joshua¹,Khot Umesh N.¹,Martinez Kathryn A.²³,Brophy Todd J.¹,West Lucianne⁴,Cristiani Cari⁴,Block‐Beach Hunter²,Hohman Jessica A.²³,Sobol Tim¹,Brooksbank Jeremy A.¹,Surratt Michael B.²,Babiuch Christopher²,Kapadia Samir R.¹,Tang W.H. Wilson¹,Estep Jerry D.⁵,Starling Randall C.¹

Affiliation:

1. Department of Cardiovascular Medicine Heart, Vascular and Thoracic Institute, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic Cleveland OH USA

2. Primary Care Institute Cleveland OH USA

3. Center for Value‐Based Care Research, Cleveland Clinic Cleveland OH USA

4. Department of Pharmacy Cleveland Clinic Cleveland OH USA

5. Department of Cardiovascular Medicine Cleveland Clinic Florida Weston FL USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.3067

Reference12 articles.

1. Medical Therapy for Heart Failure With Reduced Ejection Fraction

2. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction

3. Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems

4. Putting the “Optimal” in Optimal Medical Therapy

5. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2is) Following FDA Approval for Heart Failure With Preserved and Mildly Reduced Ejection Fraction;Journal of Cardiac Failure;2024-04